PATENT DUCTUS ARTERIOSUS DEVICE OCCLUSION

Objectives: To determine immediate outcomes and complication rate oftranscatheter closure of patent ductus arteriosus. Study Design: Retrospective analysis.Setting: CPE Institute of cardiology. Period: 2009 to May 2016. Materials and Methods:Two hundred and seventy four (274) results of transcatheter occlusion of PDA performed bypediatric cardiologists. All patients who underwent PDA occlusion regardless of their weighteither by ADO device or SHSMA occlude were included for analysis. SPSS V23 was used fordata processing. Frequency was calculated for qualitative variables and mean for quantitativeones. Results: The mean age of study participants was 9.57+8.82 years. There was femalepredominance with 65.7% females and 34.3% males. Regarding severity of PDA, 90 (32.8%)patients were presented with large PDA, 70 (25.5%) with moderately large PDA, 107 (39.1%)with moderate PDA and only 6 (2.2%) were presented with small sized PDA. Classical conicalshaped PDA was most common manifestation, diagnosed in 66.8% patients and long ampullashaped in 70 (25.5%) patients. Regarding complications, device embolization occurred in onepatient. Residual PDA in catheterization lab was present in 4 (1.5%) patients. Radial pulse lossoccurred in 6 (2.2%) patients for which heparin infusion was started until the pulse becamepalpable. Blood transfusion was required in 3 (1.1%) patients due to excessive blood lossduring the procedure. Mild left pulmonary artery obstruction due to protrusion of pulmonaryend of device occurred in 2 (0.7%) patients. Device protrusion into aorta was noted in only 16(5.8%), in all of these patients there was no aortic flow obstruction. Overall success rate was99.63%. There was no procedure related mortality. Conclusion: Percutaneous patent ductusarteriosus closure is safe with minimum number of complications. Pulse loss, protrusion o aorticend of device into aorta and residual PDA in cath lab (resolved within 24 hours) are commonprocedural complications.